Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
91 hedge funds and large institutions have $188M invested in Eiger BioPharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 24 reducing their positions, and 13 closing their positions.
66,500% more call options, than puts
Call options by funds: $666K | Put options by funds: $1K
46% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
3% less funds holding
Funds holding: 94 → 91 (-3)
25% less capital invested
Capital invested by funds: $252M → $188M (-$64.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.29M |
| 2 |
BlackRock
New York
|
+$2.1M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$2.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 5 |
CA
CHI Advisors
New York
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$12.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.37M |
| 3 |
Morgan Stanley
New York
|
-$3.53M |
| 4 |
D.E. Shaw & Co
New York
|
-$533K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$525K |
EIGR Hedge Fund Activity: Q2 2022 in Review
91 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2022, worth a combined $188M — down 25% from $252M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EIGR and 12 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 35 added.
The largest buyer was 683 Capital Management, adding an estimated $3.29M. The largest seller was VR Adviser, exiting entirely with an estimated $12.2M sold.
- 91 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2022, down from 94 in Q1 2022.
- Funds reported $188M of Eiger BioPharmaceuticals, Inc. stock for Q2 2022, down 25% quarter-over-quarter.
- 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2022 and 13 closed out, a net change of -1 holder.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2022 was 683 Capital Management, an estimated $3.29M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2022 was VR Adviser, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2022.